Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong Province, China.
Department of Oncology, Affiliated Qujing Hospital of Kunming Medical University, QuJing, Yunnan Province, China.
J Cancer Res Ther. 2023 Aug;19(4):849-865. doi: 10.4103/jcrt.jcrt_723_23.
With the addition of immunotherapy, lung cancer, one of the most common cancers with high mortality rates, has broadened the treatment landscape. Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC) and are now used as the first-line therapy for metastatic disease, consolidation therapy after radiotherapy for unresectable locally advanced disease, and adjuvant therapy after surgical resection and chemotherapy for resectable disease. The use of adjuvant and neoadjuvant immunotherapy in patients with early-stage NSCLC, however, is still debatable. We will address several aspects, namely the initial efficacy of monotherapy, the efficacy of combination chemotherapy, immunotherapy-related biomarkers, adverse effects, ongoing randomized controlled trials, and current issues and future directions for immunotherapy in early-stage NSCLC will be discussed here.
随着免疫疗法的加入，肺癌作为一种死亡率较高的常见癌症，其治疗领域已经拓宽。免疫检查点抑制剂在治疗非小细胞肺癌（NSCLC）方面显示出显著的疗效，现已被用作转移性疾病的一线治疗、不可切除的局部晚期疾病放疗后的巩固治疗，以及可切除疾病手术后化疗的辅助治疗。然而，在早期非小细胞肺癌患者中使用辅助和新辅助免疫疗法仍存在争议。我们将讨论几个方面，即单药治疗的初始疗效、联合化疗的疗效、免疫治疗相关生物标志物、不良反应、正在进行的随机对照试验，以及早期非小细胞肺癌免疫治疗的当前问题和未来方向。
